Anti-ACADL/LCAD antibody (ab152160)
Key features and details
- Rabbit polyclonal to ACADL/LCAD
- Suitable for: WB, IHC-P
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-ACADL/LCAD antibody
See all ACADL/LCAD primary antibodies -
Description
Rabbit polyclonal to ACADL/LCAD -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Pig -
Immunogen
Recombinant fragment corresponding to Human ACADL/LCAD aa 1-134 (N terminal).
Database link: P28330 -
Positive control
- Recombinant Human ACADL/LCAD protein (ab114591) can be used as a positive control in WB. Human hepatoma tissue; H1299 and HCT116 whole cell lysates.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 78.99% PBS, 1% BSA, 20% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab152160 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/500 - 1/3000. Predicted molecular weight: 48 kDa.
|
|
IHC-P |
1/100 - 1/1000.
|
Notes |
---|
WB
1/500 - 1/3000. Predicted molecular weight: 48 kDa. |
IHC-P
1/100 - 1/1000. |
Target
-
Pathway
Lipid metabolism; mitochondrial fatty acid beta-oxidation. -
Involvement in disease
Defects in ACADL are a cause of acyl-CoA dehydrogenase very long-chain deficiency (ACADVLD) [MIM:201475]. An inborn error of mitochondrial fatty acid beta-oxidation which leads to impaired long-chain fatty acid beta-oxidation. It is clinically heterogeneous, with three major phenotypes: a severe childhood form characterized by early onset, high mortality and high incidence of cardiomyopathy; a milder childhood form with later onset, characterized by hypoketotic hypoglycemia, low mortality and rare cardiomyopathy; an adult form, with isolated skeletal muscle involvement, rhabdomyolysis and myoglobinuria, usually triggered by exercise or fasting. -
Sequence similarities
Belongs to the acyl-CoA dehydrogenase family. -
Cellular localization
Mitochondrion matrix. - Information by UniProt
-
Database links
- Entrez Gene: 33 Human
- Entrez Gene: 396931 Pig
- Omim: 609576 Human
- SwissProt: P28330 Human
- SwissProt: P79274 Pig
- Unigene: 471277 Human
-
Alternative names
- ACAD4 antibody
- ACADL antibody
- ACADL_HUMAN antibody
see all
Images
-
Immunohistochemical analysis of paraffin-embedded Human hepatoma tissue, staining ACADL/LCAD using ab152160 at a 1/500 dilution.
-
All lanes : Anti-ACADL/LCAD antibody (ab152160) at 1/1000 dilution
Lane 1 : H1299 whole cell lysate
Lane 2 : HCT116 whole cell lysate
Lysates/proteins at 30 µg per lane.
Predicted band size: 48 kDa
10% SDS PAGE
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab152160 has been referenced in 1 publication.
- Huang YW et al. Dysregulated Free Fatty Acid Receptor 2 Exacerbates Colonic Adenoma Formation in ApcMin/+ Mice: Relation to Metabolism and Gut Microbiota Composition. J Cancer Prev 26:32-40 (2021). PubMed: 33842404